Vista Partners Initiates Coverage on Targeted Medical Pharma (OTCQB:TRGM). - Video Research Alert on InvestmentPitch.com
(Thomson Reuters ONE) -
Vancouver, British Columbia, November 25, 2013 - San Francisco-based Vista
Partners has initiated coverage on Targeted Medical Pharma (OTCQB:TRGM).
Following the release of the company's 3rd quarter financial results, Analyst
Ross Silver gives the company a 12 month target price of $2.75, a premium of
248% to the $0.79 price the day the report was issued.
InvestmentPitch.com has produced a "video research alert" about Targeted Medical
Pharma based on this report. If this link is not enabled, please visit
www.InvestmentPitch.com and enter "Targeted Medical" in the search box.
The company reported total revenue of $6.9 million for the nine months ending
September 30, 2013, an increase of 41% over the nine months ended September
30, 2012.
The company is a Los Angeles-based biotechnology company that develops and
commercializes nutrient-based and pharmaceutical therapeutic systems.
Its patented prescription medical food products for the treatment of chronic
disease, including pain syndromes, peripheral neuropathy, hypertension, obesity,
sleep and cognitive disorders, are currently sold in the United States, to
pharmacies through a network of distributors, and directly to physicians, who
dispense medical foods and other pharmaceutical products through their office
practices.
The company manufacturers 10 proprietary medical foods, and recently launched
its first dietary supplement, "Clearwayz".
Analyst Ross Silver stated, "The company currently sells into 34 states and is
looking to sell into all 50 and plans to expand into international markets. The
U.S. market projected to be $2 billion plus and growing 10%+ annually."
The company currently trades at $1.00, below the $2.75 target price, and with
23.9 million shares outstanding, the company is capitalized at $23.9 million.
For more information, please visit the company's website www.tmedpharma.com or
call 310-474-9809.
The company's investor relations is handled by Jeff Ramson of ProActive Capital
Group. He can be reached at 646-863-6983 or by email at
jramson(at)proactivecapital.com.
For more information about Vista Partners or to obtain a copy of their research
report, contact your nearest Vista Partners office. Their branches are listed on
their website at www.vistapglobal.com.
About InvestmentPitch
InvestmentPitch.com, a multimedia company that provides a combined solution for
creating and hosting financial video content, and distributing it across
multiple platforms to investors and financial professionals, specializes in
producing corporate interviews and three minute videos based on news releases
and research reports. Please visit InvestmentPitch.com and browse our extensive
library of investment videos.
CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
604-684-5524
bmorgan(at)investmentpitch.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: InvestmentPitch via GlobeNewswire
[HUG#1745580]
Unternehmensinformation / Kurzprofil:
Datum: 25.11.2013 - 16:20 Uhr
Sprache: Deutsch
News-ID 320131
Anzahl Zeichen: 3694
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 167 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vista Partners Initiates Coverage on Targeted Medical Pharma (OTCQB:TRGM). - Video Research Alert on InvestmentPitch.com"
steht unter der journalistisch-redaktionellen Verantwortung von
InvestmentPitch (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
